A selective p53 activator and anticancer agent to improve colorectal cancer therapy

A selective p53 activator and anticancer agent to improve colorectal cancer therapy

Summary: Impairment of the p53 pathway is a critical event in cancer. Therefore, reestablishing p53 activity has become one of the most appealing anticancer therapeutic strategies. Here, we disclose the p53-activating anticancer drug (3S)-6,7-bis(hydroxymethyl)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]...

Full description

Bibliographic Details
Main Authors: Helena Ramos, Maria I.L. Soares, Joana Silva, Liliana Raimundo, Juliana Calheiros, Célia Gomes, Flávio Reis, Filipe A. Monteiro, Cláudia Nunes, Salette Reis, Bartolomeo Bosco, Silvano Piazza, Lucília Domingues, Petr Chlapek, Petr Vlcek, Pavel Fabian, Ana Teresa Rajado, A.T.P. Carvalho, Renata Veselska, Alberto Inga, Teresa M.V.D. Pinho e Melo, Lucília Saraiva
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Cell Reports
Subjects:
p53 activator
anticancer drug
colorectal cancer
targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124721002965

Internet

http://www.sciencedirect.com/science/article/pii/S2211124721002965

Similar Items